Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of Nirmatrelvir–Ritonavir Against the Development of Post–COVID-19 Conditions Among U.S. Veterans
George N. Ioannou, Kristin Berry, Nallakkandi Rajeevan, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 11, pp. 1486-1497
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection
Linda N. Geng, Hector Bonilla, Haley Hedlin, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 9, pp. 1024-1024
Open Access | Times Cited: 35
Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study
Huwen Wang, Yuchen Wei, C.T. Hung, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 10, pp. 1130-1140
Open Access | Times Cited: 15
Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis
Juan Jiang, Yantong Li, Qiaoling Jiang, et al.
Journal of Infection (2024) Vol. 89, Iss. 2, pp. 106190-106190
Closed Access | Times Cited: 10
The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis
Gangqiang Sun, Ke Lin, Jingwen Ai, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1505-1513
Closed Access | Times Cited: 9
Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial
Mitsuaki Sawano, Bornali Bhattacharjee, César Caraballo, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 1
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, et al.
Antiviral Research (2024) Vol. 229, pp. 105958-105958
Open Access | Times Cited: 7
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity
Sunil J. Wimalawansa
Heliyon (2024) Vol. 10, Iss. 15, pp. e34691-e34691
Open Access | Times Cited: 4
Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans
Liang En Wee, Jue Tao Lim, An Ting Tay, et al.
Clinical Microbiology and Infection (2024) Vol. 31, Iss. 1, pp. 93-100
Closed Access | Times Cited: 4
Vaccine Effectiveness Among 5- to 17-year-old Individuals with Prior SARS-CoV-2 Infection: An EHR-Based Target Trial Emulation Study from the RECOVER Project
Jiajie Chen, Yuqing Lei, Qiong Wu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation
Yuchen Wei, Christopher Boyer, Katherine Min Jia, et al.
Emerging Microbes & Infections (2025)
Open Access
Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data
Myriam Gharbi, Rose Chang, Tracy Guo, et al.
Infection (2025)
Open Access
Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras
George N. Ioannou, Kristin Berry, Nallakkandi Rajeevan, et al.
Clinical Infectious Diseases (2025)
Closed Access
Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study
Emma Birnie, Magda Vergouwe, Brent Appelman, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 4
Open Access
Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation
Lei Yan, David Bui, Yuli Li, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 3
Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program
Steve Johnson, Sajjad Abedian, Til Stürmer‎, et al.
Diabetes Care (2024) Vol. 47, Iss. 11, pp. 1930-1940
Closed Access | Times Cited: 3
Risk of Post-Acute Sequelae of COVID-19 and Oral Antivirals in Adults Aged Over 60 years: A Nationwide Retrospective Cohort Study
Hye Jin Joo, Eunji Kim, Kyungmin Huh, et al.
International Journal of Infectious Diseases (2025), pp. 107850-107850
Open Access
Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review
Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, et al.
Therapeutic Advances in Infectious Disease (2025) Vol. 12
Open Access
Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach
Daniel O. Griffin
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 9
Open Access | Times Cited: 2
COVID-19 vaccination modified the effect of nirmatrelvir–ritonavir on post-acute mortality and rehospitalization: a retrospective cohort study
Huwen Wang, Yuchen Wei, Guozhang Lin, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Long COVID symptoms after 8-month recovery: persistent static lung hyperinflation associated with small airway dysfunction
Po‐Chun Lo, Jia‐Yih Feng, Yi‐Han Hsiao, et al.
Respiratory Research (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies
Fernando Valerio-Pascua, Fernando Baires, Anupamjeet Kaur Sekhon, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
The Omicron Variant Is Associated with a Reduced Risk of the Post COVID-19 Condition and Its Main Phenotypes Compared to the Wild-Type Virus: Results from the EuCARE-POSTCOVID-19 Study
Francesca Bai, Andrea Santoro, Pontus Hedberg, et al.
Viruses (2024) Vol. 16, Iss. 9, pp. 1500-1500
Open Access | Times Cited: 1
Long COVID in Women Veterans Residing in Underserved, Socioeconomically Disadvantaged Neighborhoods of Chicago
Zane Elfessi, Jessica Gardner, Howard S. Gordon, et al.
Population Health Management (2024) Vol. 27, Iss. 3, pp. 227-230
Closed Access
Long COVID: a consequence of chronic post-infectious inflammation!
Joseph M. Blondeau
Expert Review of Respiratory Medicine (2024)
Closed Access
Neglected Effective Early Therapies against COVID-19: Focus on Functional Foods and Related Active Substances. A Review
Alberto Donzelli
(2023)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top